Simultaneous FMRI and NIRS to Estimate Brain Cerebral Metabolism
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01825096|
Recruitment Status : Completed
First Posted : April 5, 2013
Last Update Posted : January 5, 2017
The principal advantages of functional magnetic resonance imaging (fMRI) with blood-oxygenation- level-dependent (BOLD) contrast for studying brain function are: non-invasiveness, ubiquitous availability, relatively high spatiotemporal resolution, and the ability to map function over the entire brain. Thus, BOLD fMRI is the most widely applied technology to study healthy brain function and pathophysiology associated with disease. In studies of drug abuse and psychiatric illness though, normal assumptions mapping BOLD signals to neurometabolism may be violated. Generally, these effects are ignored, resulting in large study-to-study variability.
Quantitative fMRI (qfMRI) measures metabolism directly and is more suitable for studies of drug abuse and psychiatric illness. However, qfMRI is too complex for routine use. Cerebral metabolism during brain activation during visual stimulation measured with a new fMRI approach that is simple enough for clinical applications will be compared to CMRO2 activation measured using standard qfMRI.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||1 participants|
|Official Title:||Multi-Modal fMRI/NIRS for Estimation of CMRO2 for Neuroimaging Studies of Drug Abuse and Psychiatric Illness Problems|
|Study Start Date :||March 2012|
|Actual Primary Completion Date :||December 2015|
|Actual Study Completion Date :||December 2015|
No intervention. Participants are scanned at baseline.
- Changes in brain activity associated with visual stimulation [ Time Frame: cross-sectional, start and up to 6 minutes ]CMRO2 brain activation in visual cortex associated with visual stimulation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01825096
|United States, Massachusetts|
|McLean Imaging Center|
|Belmont, Massachusetts, United States, 02478|
|Principal Investigator:||Lisa D Nickerson, PhD||Mclean Hospital|